By Abigail Townsend
Date: Thursday 20 Apr 2023
LONDON (ShareCast) - (Sharecast News) - Haleon posted first-quarter sales ahead of expectations on Thursday, boosted by a strong cold and flu season.
The consumer healthcare giant said revenues in the three months to 31 March rose 9.9% on an organic basis, to £2.99bn, well above analyst forecasts, while prices increased by 7.1%. Growth was seen across oral health, pain relief and digestive health as well as respiratory health.
On a geographical basis, Haleon reported double-digit growth in Europe, Middle East and Africa, Latin America and Asia Pacific, and mid-single digit growth in North America.
China benefited from the removal of pandemic restrictions, Haleon noted, as well as increased cases of Covid, colds and flu.
As a result, the blue chip said it now expected full-year 2023 organic revenue growth to be at the upper end of its 4% to 6% guidance range.
Haleon, which was spun out of GSK last summer, was updating on trading ahead of its annual general meeting. It is scheduled to publish a full first-quarter trading statement in early May.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 325.80p |
Change Today | 4.60p |
% Change | 1.43 % |
52 Week High | 353.55 |
52 Week Low | 308.55 |
Volume | 9,421,445 |
Shares Issued | 9,132m |
Market Cap | £29,753m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Latest | Previous | |
---|---|---|
Final | Interim | |
Ex-Div | 14-Mar-24 | 24-Aug-23 |
Paid | 16-May-24 | 05-Oct-23 |
Amount | 4.20p | 1.80p |
Time | Volume / Share Price |
16:39 | 4,231 @ 325.80p |
16:39 | 7,769 @ 325.80p |
16:38 | 121 @ 325.80p |
16:38 | 11,879 @ 325.80p |
16:38 | 10,771 @ 325.80p |
You are here: research